Individual usage of glucagon like peptide 1 receptor agonists reduced the risk of hospitalization due to alcohol and substance use disorders.
A recent meta-analysis of 69 clinical trials found the risk for ischemic optic neuropathy from GLP-1 therapy is too low to be ...
Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently a pressing public health issue associated with ...
Glucagon-like peptide 1 receptor agonists and fenofibrates may protect patients with type 2 diabetes against diabetic macular ...
The term "nonalcoholic fatty liver disease" (NAFLD) has long been used to describe liver steatosis not related to excessive alcohol consumption ...
Some people are not taking weight-loss medications responsibly, the physician says, and don't realize their full implications ...
Health on MSN1d
Study Finds Nearly Half of People on Obesity Drugs Drink Less—But Do Scientists Know Why?New research found that some anti-obesity medications such as Wegovy and Zepbound may prompt people to drink less. These ...
1d
Semaglutide use in diabetes patients is linked to a higher risk of NAION, a rare eye condition. A Danish-Norwegian study ...
GLP-1 agonists substantially slowed kidney deterioration and failure, independent of diabetes status. The most extensive and ...
Treatment with GLP-1RAs was associated with significant improvements in obstructive sleep apnea-related health outcomes.
But weight loss alone does not explain the drugs’ benefits. Both Holst and Sattar pointed to a discontinued GLP-1 drug once ...
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce the risk for clinically important kidney and cardiovascular disease outcomes in individuals with type 2 diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback